M06.359 Rheumatoid nodule, unspecified hip

Name of the Condition

• Rheumatoid nodule, unspecified hip

Summary

Rheumatoid nodule, unspecified hip is a localized extra-articular manifestation of rheumatoid arthritis (RA) involving firm, subcutaneous nodules in the hip region. These nodules are composed of inflammatory tissue and are associated with chronic, seropositive RA. They may occur in other conditions but are most strongly linked to RA. Diagnosis relies on clinical recognition and correlation with underlying joint disease.

Causes

Rheumatoid nodules form due to chronic inflammation and immune complex deposition in subcutaneous tissues. They are associated with severe, long-standing RA, particularly in patients with high rheumatoid factor or anti-CCP antibody levels. The exact pathogenesis involves dysregulated immune responses and fibroblast activation, leading to nodule formation. They may also develop at sites of trauma or injection.

Risk Factors

• Severe, long-standing rheumatoid arthritis (especially seropositive disease).
• High rheumatoid factor or anti-CCP antibody titers.
• Presence of other extra-articular RA manifestations (e.g., vasculitis).
• Chronic inflammation and immune dysregulation.
• Trauma or pressure to affected areas.

Symptoms

• Firm, movable subcutaneous nodules in the hip area.
• Nodules may be painless or tender.
• May be associated with underlying joint inflammation.

Diagnosis

Diagnosis is primarily clinical, based on the presence of firm, subcutaneous nodules in the hip region and correlation with a history of rheumatoid arthritis. Imaging (e.g., ultrasound or MRI) may be used to confirm the presence of nodules and rule out other conditions. Biopsy is rarely needed but can confirm the diagnosis if uncertainty exists. Laboratory tests for rheumatoid factor and anti-CCP antibodies support the association with RA.

Treatment Options

Treatment focuses on managing underlying rheumatoid arthritis, as nodules often improve with disease control. Options include disease-modifying antirheumatic drugs (DMARDs), biologic agents, or targeted synthetic DMARDs. Local measures, such as cushioning or avoiding pressure, may reduce discomfort. Surgical removal is rarely necessary unless nodules cause functional impairment or complications.

Prognosis and Follow-Up

Prognosis depends on the severity of underlying RA and response to treatment. Nodules may persist, regress, or fluctuate with disease activity. Regular follow-up with a rheumatologist is recommended to monitor RA progression and adjust therapy. Nodule size or symptoms should be documented during visits to track changes.

Complications

• Ulceration or infection if nodules break through the skin.
• Functional impairment if nodules affect mobility or pressure points.
• Psychosocial impact due to visible nodules.

Lifestyle & Prevention

• Manage RA effectively with prescribed medications to reduce nodule formation.
• Avoid trauma or pressure to the hip area to prevent nodule development or irritation.
• Maintain regular follow-up with healthcare providers to monitor disease activity.

When to Seek Professional Help

Seek medical attention if nodules become painful, ulcerate, increase in size, or affect mobility. Prompt evaluation is also recommended if new nodules appear or if there are signs of infection (e.g., redness, drainage).

Tips for Medical Coders

Document the location (unspecified hip) and confirm the association with rheumatoid arthritis. Ensure clinical correlation is noted, as nodules may occur in other conditions. Code M06.359 is specific to rheumatoid nodules in the unspecified hip; do not use this code for bilateral or specified hip involvement.